Introducing Our New SOP on Skeletal Muscle Fiber Typing
We are excited to announce the release of our latest Standard Operating Procedure (SOP) titled “Skeletal Muscle Fiber Typing & Cross-Sectional Area Analysis using Immunofluorescence Staining for Mice,” developed by our Basic Science Trainee Committee (BSTC) member Shatha Atieh, Phd Student at uOttawa. This SOP aims to provide a comprehensive, step-by-step protocol for staining and analyzing skeletal muscle fibers from any muscle group in various mouse models. This SOP aims to provide a comprehensive, step-by-step protocol for staining and analyzing skeletal muscle fibers from any muscle group in various mouse models.
Key Protocol Features
This SOP includes detailed methods for quantifying fiber-type composition using immunofluorescence staining to detect myosin heavy chain (MyHC) isoforms in individual fibers. Commonly used primary antibodies include MyHC-I, MyHC-IIA, and MyHC-IIB, along with laminin for measuring cross-sectional areas (CSA), providing insights into muscle function and health.
Furthermore, the SOP guides researchers in assessing changes in muscle fiber size due to various factors such as disease or exercise by measuring the CSA of individual muscle fibers and visualizing fiber size distributions through statistical analysis.
We invite all researchers to download the full SOP below:
Download Full SOP
Feel free to explore the potential of this SOP in your research, leave your feedback and contribute to advancing the understanding of skeletal muscle physiology!
Visit Our SOP Library
As our SOP Library continues to grow, we are inviting contributions from across the Canadian neuromuscular community. If you have SOPs that could support shared learning and strengthen research practices nationwide, we encourage you to get involved, review our current collection and download our SOP template. For more information about sharing your SOPs with the us, please contact Erin Beattie, our Network Manager.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.